sorafenib has been researched along with beta-escin in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (beta-escin) | Trials (beta-escin) | Recent Studies (post-2010) (beta-escin) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 14,137 | 211 | 6,278 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brandt, R; Dredge, K; Hammond, E | 1 |
| Dong, H; Gao, W; Ma, L; Man, S; Yang, L; Yao, J | 1 |
2 other study(ies) available for sorafenib and beta-escin
| Article | Year |
|---|---|
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Saponins; Sorafenib | 2012 |
Combinatorial treatment of Rhizoma Paridis saponins and sorafenib overcomes the intolerance of sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Metabolomics; Mice; Rhizome; Saponins; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |